Within past decade substantial progress has been made in 
our understanding of the molecular mechanisms by which low
intense inflammation might induce metabolic disorders, such as 
diabetes and metabolic syndrome. Gal-3 is low molecular 
chimaera-type galectin, which highly expressed in a variety of 
cells that has been recently recognized as a biomarker of 
cardiovascular fibrosis and inflammation. The main biological 
role of Gal-3 is regulation of cell migration, adhesion, growth and 
differentiation, modulation of mRNA splicing, as well as Gal-3 
affects extracellular matrix interactions, angiogenesis and 
malignancy. Recent clinical studies have shown that Gal-3 in both 
general and diabetic populations might contribute increased risk 
of CV outcomes. The possible capacity of Gal-3 to predict 
diabetes manifestation and development beyond other classical 
CV risk factors and CV diseases requires more investigations. 
This editorial comment is dedicated a consideration of possible 
role of Gal-3 as diagnostic and predictive biomarker in patients 
with diabetes.